A single 19-Gy dose of stereotactic body radiotherapy (SBRT) achieved a 92.9% biochemical relapse-free survival rate at three years in men with low- or intermediate-risk prostate cancer, according to a multicentre study published in JAMA Oncology. The trial, led by T. Zilli et al., indicates that urethra-sparing SBRT provides effective disease control with manageable toxicity levels, potentially shortening treatment timelines for eligible patients.
How does single-fraction SBRT compare to conventional radiotherapy?
Conventional external beam radiotherapy typically requires multiple sessions over several weeks. In contrast, the protocol tested by Zilli et al. utilizes a single 19-Gy fraction. By employing real-time prostate movement tracking and urethra-sparing techniques, researchers achieved a 92.9% success rate in preventing biochemical relapse over a median follow-up of 55.3 months. While traditional methods are the established standard, this single-session approach aims to reduce the overall patient burden and hospital visit frequency.
What are the reported side effects of high-dose SBRT?
Clinical data shows that treatment-related toxicity remains low for most participants. According to the study, grade 2 genitourinary adverse events occurred in 9.8% of patients, while grade 2 gastrointestinal events were reported in 4.9% at the three-year mark. One patient experienced a grade 3 proctitis event at 12 months. Sexual health outcomes showed more frequent impacts, with grade 2 or higher erectile dysfunction rising from 21.4% at baseline to 38.4% three years post-treatment.
Real-time motion management is a critical component of modern SBRT. Because the prostate can shift due to bladder filling or bowel gas, clinicians use advanced imaging to adjust the radiation beam dynamically, protecting surrounding healthy tissue.
What does this mean for future prostate cancer care?
If larger, comparative studies confirm these findings, single-session SBRT could shift the standard of care toward outpatient-friendly protocols. Currently, the primary challenge remains long-term durability. The authors emphasize that while the early results are promising, extended follow-up is necessary to ensure the 19-Gy dose provides lasting oncological control compared to established multi-fraction regimens. This evolution in radiotherapy mirrors broader trends in oncology that prioritize shorter, higher-intensity treatment courses to improve patient quality of life.
Frequently Asked Questions
- Is single-fraction SBRT suitable for all prostate cancer patients?
No. The study focused on patients with low- or intermediate-risk disease and excluded those with significant tumour involvement in the transitional zone. - How long is the recovery time after this procedure?
As an outpatient procedure, the treatment avoids the recovery time associated with traditional surgery, though patients are monitored for potential urinary or sexual side effects over several years. - Does this replace surgery?
Radiotherapy is an alternative to surgery for localized prostate cancer. Patients should discuss the specific risks and benefits of SBRT versus prostatectomy with their urologist or radiation oncologist.
Stay Informed
Are you interested in the latest advancements in oncology and urology? Subscribe to our newsletter to receive updates on clinical trials and new treatment protocols directly to your inbox. Have questions about this study? Share your thoughts in the comments section below.
